Exenatide: approved uses, mechanism and half-life

Research summary

Synthetic form of exendin-4 and the first GLP-1 receptor agonist approved in the United States, marketed as Byetta (twice daily) and Bydureon (extended release). Approved as an adjunct to diet and exercise for glycaemic control in type 2 diabetes.

Research evidence

Regulatory review (FDA label)1 reviewed source
Controlled human trials1 reviewed source
Early or uncontrolled human studiesNone in reviewed sources
Lab & animal studiesNone in reviewed sources

How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Exenatide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Exenatide dosage evidence

Exenatide has an FDA-approved human dosage. Byetta for adults with type 2 diabetes starts at 5 mcg twice daily under the skin within 60 minutes before the morning and evening meals, and can go to 10 mcg twice daily after 1 month. A once-weekly 2 mg extended-release form was compared with 10 mcg twice daily in the DURATION-1 trial; no Bydureon or Bydureon BCise label is listed on DailyMed as of this review.

FDA Approved

Dosage evidence summary for Exenatide
Human dosing established	Yes
Route	Subcutaneous
Frequency	Twice daily before meals (Byetta); once weekly in extended-release trials
Duration studied	Continuous
Titration	Byetta: 5 mcg twice daily for 1 month, then 10 mcg twice daily based on response.
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Exenatide, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — Byetta, type 2 diabetesFDA-approved label · FDA prescribing information	Adults with type 2 diabetes mellitus	Start 5 mcg; 10 mcg after 1 month based on response	Subcutaneous, thigh, abdomen or upper arm	Twice daily, within 60 minutes before the morning and evening meals (or the two main meals, about 6 hours or more apart); never after a meal	Continuous, with diet and exercise	Glycemic control	BYETTA (exenatide) injection — FDA prescribing information, DailyMed
DURATION-1 — randomised, open-label trial (Drucker et al., 2008)Clinical trial · Phase 3 randomised non-inferiority trial (NCT00308139)	Adults with type 2 diabetes, drug-naive or on oral agents (n=295)	2 mg once weekly (long-acting release) versus 10 mcg twice daily	Subcutaneous	Once weekly versus twice daily	30 weeks	HbA1c fell 1.9% with once weekly versus 1.5% with twice daily	Drucker DJ et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes (DURATION-1). Lancet 2008

Where sources disagree

The two forms use different units and schedules: Byetta is micrograms twice a day, the extended-release form 2 mg once a week. Figures from one do not transfer to the other.
DailyMed lists Byetta (AstraZeneca) and a generic exenatide injection, but no Bydureon or Bydureon BCise label as of 2026-11-07. The once-weekly dose shown here comes from a trial, not a current US label.
The Byetta label says not to use it with other exenatide-containing products, and lists drug-induced immune thrombocytopenia from exenatide as a contraindication.

Exenatide dosage in published studies and labels →

Sequence & molecular data

Sequence and molecular data for Exenatide
Amino acid sequence	His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser
Molecular formula	C184H282N50O60S
Molecular weight	4187 g/mol
CAS number	141758-74-9
PubChem CID	45588096
FDA UNII	9P1872D4OL

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Exenatide is a 39-amino-acid peptide originally isolated from Gila monster venom that shares partial homology with human GLP-1 while resisting degradation by dipeptidyl peptidase-4. It binds the GLP-1 receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon release, and slowing gastric emptying. Because the insulinotropic effect is glucose-dependent, the risk of hypoglycaemia when used alone is low.

Studies

Research statistics

4,357 PubMed publications · 24.0% human clinical research · 317 registered trials

Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Exenatide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

Regulatory and research status for Exenatide
FDA status	Approved
Research status	Approved product (see FDA status)
Availability	Prescription-Only
WADA (sport)	Unknown / Not Listed
Library classification	FDA-Approved

How FDA approval, compounding and research-only status differ

Benefits

—

Exenatide side effects

No side effects listed yet for this entry.

Storage & stability

This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.

Exenatide: frequently asked questions

What is Exenatide?

Synthetic form of exendin-4 and the first GLP-1 receptor agonist approved in the United States, marketed as Byetta (twice daily) and Bydureon (extended release). Approved as an adjunct to diet and exercise for glycaemic control in type 2 diabetes.

How does Exenatide work?

Exenatide is a 39-amino-acid peptide originally isolated from Gila monster venom that shares partial homology with human GLP-1 while resisting degradation by dipeptidyl peptidase-4. It binds the GLP-1 receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon release, and slowing gastric emptying.

Is Exenatide FDA approved?

Yes. Exenatide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

What is the amino acid sequence of Exenatide?

Exenatide has the sequence His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, giving a chain of 39 amino acids. Its molecular formula is C184H282N50O60S.

What peptides are similar to Exenatide?

Compounds most often compared with Exenatide include Semaglutide, Tirzepatide, Retatrutide and Liraglutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This Exenatide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Exenatide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →